Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

January 12, 2023

https://www.globenewswire.com/news-release/2023/01/12/2587812/0/en/Eyenovia-Reveals-Positive-Evidence-That-Optejet-Delivery-Technology-Decreased-Inflammation-From-Preserved-Glaucoma-Solutions-Compared-to-Drops.html

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ:EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment administered via Optejet versus latanoprost+BAK administered via standard eye drops.

Read more at globenewswire.com

Related news for (EYEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.